Our journey began with a deep passion to understand biology at the molecular level.
For more than 20 years, our team at Seoul National University has pioneered protein structure prediction and design technologies, earning global recognition for scientific excellence.
Where expertise sparks innovation
Driven by deep domain expertise, Galux was founded in 2020 with a passion to streamline drug development and address the limitations of conventional discovery through AI.
Technological excellence sets us apart
We are at the forefront of AI-driven protein design as one of the few groups to have successfully demonstrated de novo antibody design. Our platform's unprecedented accuracy and generalizability have been validated through the de novo design of antibodies, one of the most challenging protein classes, across multiple therapeutic targets.
Shaping the future of AI drug discovery and development
This is just the beginning. We move fast to accelerate the arrival of the next generation of medicine, so that more people living today can benefit.
